Deals of the Week: AstraZeneca’s Neuroscience Deals, Verastem/Pfizer, Alnylam/Ascletis
Executive Summary
AstraZeneca’s neuroscience innovative medicines unit (iMED) begins to take shape through a pair of deals with Link Medicine Corp. and with four academic labs.
You may also be interested in...
AstraZeneca Teams With Vanderbilt In Neuroscience Pact
Vanderbilt University’s neuroscience research group reaches its latest agreement with a pharma, this one covering compounds that treat symptoms of Alzheimer’s disease and schizophrenia by modulating a receptor in new ways.
A New Industry-Academic Model: Novartis And Penn Make A Splash In Cancer Immunotherapy
Novartis’ deal with the University of Pennsylvania around cancer immunotherapies based on chimeric antigen receptor technologies developed in the lab of Penn’s Carl June comes at an opportune time. The Big Pharma is fighting to preserve its number two ranking in oncology and Penn’s high-profile, albeit much smaller, alliance with AstraZeneca in neurodegenerative disease is winding down.
Australian Biotech Bionomics Acquires Biogen-Idec Spin-off Eclipse Therapeutics
Aussie biotech Bionomics acquires Eclipse Therapeutics, which is developing drug candidates that target cancer stem cells.